Here we seek to develop a more effective and targeted electroporation device for the clinical treatment of cancerous solid tumors. The application of using electroporation to transfect therapeutic agents into a tumor cells in the clinician setting is an exciting approach to a targeted treatment of cancer. The challenge for this work is to further develop a clinical electroporation device that will use the phenomenon of wave interference to produce a targeted electroporation waveform to increase the effectiveness of transfection.
OncoSec Medical Incorporated is a small biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat local solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize the detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. This proposal addresses the need to optimize the electroporation product by using the interference phenomenon to target and control a reversible electroporation waveform.
